Search PubMed⌕ Search

Biomedical subjects

C Vogel

Publications and source records attributed to C Vogel.

At least 91 records · Page 5Linked to original sources
PubMed1984

Life history of Hanuman langurs (Presbytis entellus). Reproductive parameters, infant mortality, and troop development.

Longitudinal data of reproductive parameters from two langur troops (Presbytis entellus) at Jodhpur, Rajasthan, India, are presented. Females can reach menarche at approximately 29 months of age and conceive about 5 months later. Gestation length is about 200 days, average cycling length is 24 days, and mean interbirth interval 15.3 months. Postpartum amenorrhea, which ranges from 80-140 days will be reduced to 23-80 days in cases of stillbirths or early losses of infants, a fact that bears consequences in regard to the discussion of infanticide and reproductive advantage. Troop development showed distinct differences in two neighboring troops, especially in number of surviving female infants until sexual maturity. Both troops taken together, 77.9% of the newborns reached the infant-II stage (6 months), 59.3% survived until their mother's next infant (average, calculated for the mean birth interval of 15.3 months), and only 35.9% completed the 2nd year of life.

Age Factors↗
PubMed1983

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.

The Southeastern Cancer Study Group, in a prospectively randomized study involving patients with advanced breast cancer, has compared a low dose intermittently administered five-drug regimen including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) with an aggressively administered three-drug regimen including cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF). CAF induced more responses and more complete responses and a longer duration of disease control. However, only a marginal difference was demonstrated in overall survival between the two regimens (p = less than 0.10). Patients with a good risk pattern of metastases, i.e. those with nodular local chest wall recurrence, nodular pulmonary metastases, or bone-only metastases were more likely to achieve a response and survive longer than those with a poor risk pattern, i.e. lymphangitic pulmonary metastases, pleural effusion with chest wall ulceration, or widespread metastases, including hepatic. All of the differences between the two regimens were noted in the good risk pattern groups. CAF provided no additional benefit to patients presenting with poor risk patterns of metastases. Adriamycin-containing combinations may achieve a greater degree of tumor cell kill in certain subsets of patients with advanced breast cancer, but this provides only a marginal increase in survival.

Antineoplastic Agents↗
PubMed1983

Southeastern Cancer Study Group: breast cancer studies 1972-1982.

During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.

Adult↗
PubMed1982

[Improvement of the flow properties of the blood of patients by low-molecular hydroxyethyl starch (Expafusin)].

10 patients with various diseases causing elevated ESR-values and impaired flow properties of blood received infusions of 500 ml of low molecular weight hydroxyethylstarch (HES 6%, Expafusin) within approximately 30 minutes. Measurements of rheological parameters for several hours after infusion showed a statistically significant decrease of apparent whole blood viscosity and of plasma viscosity. RBC aggregation was slightly, but statistically significantly reduced, whereas RBC filterability remained unchanged. These data obtained with blood from patients with altered flow properties of blood agree very well with former results obtained in healthy volunteers.

Adult↗